Q-omics provides the consensus-scored AZIN2 profile across patient tissues and cancer cell-line models. AZIN2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, AZIN2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, AZIN2 RNA expression shows 18,996 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where AZIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AZIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AZIN2 survival associations across molecular data types. AZIN2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AZIN2 RNA expression–survival associations across cancer types. High AZIN2 expression shows unfavorable associations in OV, but favorable associations in LUAD, SKCM, BRCA, DLBC and CHOL. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for AZIN2 RNA expression.
This table summarizes AZIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AZIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AZIN2 shows lower tumor expression in KICH and higher tumor expression in KIRC, LUAD, HNSC, LIHC and BRCA. The KIRC box plot shows higher AZIN2 RNA expression in tumor versus normal tissue (log2 FC = +0.585, t-test p < 0.001).
This table shows molecular features associated with AZIN2 in patient tissues and cancer cell lines. In patient samples, AZIN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AZIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
